NCT05296798: A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

Breast Cancer Type: HER2+
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Therapeutic Antibody, Chemotherapy, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have breast cancer that is both HER2+ & ER+
Exclusions: Patients with prior systemic non-hormonal anti-cancer therapy in the metastatic breast cancer (MBC) or advanced breast cancer (ABC) setting (Note: Up to one line of single-agent endocrine therapy given in the metastatic or locally advanced setting will be allowed); Patients with prior anti-HER2 treatment, except Phesgo; Patients with prior treatment of a selective estrogen receptor degrader (SERD) (e.g. fulvestrant, Zoladex, Lupron, elacestrant); Patients with known active uncontrolled or symptomatic central nervous system (CNS) metastases or leptomeningeal disease

Comments are closed.

Up ↑